$3.640
-0.050 (-1.36%)At close
Price Predictions
Open in app to unlock longer-horizon forecasts.
IXHL Prediction & Forecast by Similar Chart Analysis
Alphio's IXHL stock price prediction model matches the current Incannex Healthcare Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $3.51 (-3.50%). The 1-week path is $3.43 (-5.85%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
Should I Buy Incannex Healthcare Inc Stock?
Incannex Healthcare Inc is a good buy right now due to its current price of 3.64, which is below its Fibonacci resistance level of 4.016, indicating potential for upward movement. Additionally, the RSI is at 65.24, suggesting the stock is approaching overbought territory but still has room for growth. The recent share buyback program reflects management's confidence in the company's valuation, which is a positive signal for long-term investors. However, the main risk is the negative net income of -6,640,000 in the latest quarter, which indicates ongoing financial challenges.
IXHL stock price ended at $3.64 on Friday, after losing -1.36%
Incannex Healthcare Inc (IXHL) last closed at $3.64, losing -1.36%. These facts feed the 1-day and 1-week IXHL price prediction above.
Forecast Drivers
Incannex Healthcare Inc (IXHL) forecast drivers combine similar chart patterns, seasonality, and moving averages.
Similar patterns
Bullish
Seasonality
Bearish
SMA 20
Bullish
SMA 200
Bearish
Similar Chart Patterns
Stocks whose recent price path most closely matches IXHL, ranked by similarity.
Seasonality analysis for IXHL
Historically the probability of a positive August return for IXHL is 0.00%. February offers the highest probability of a positive month at 18.97%, while April is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.